LENSAR SG&A Expenses 2019-2024 | LNSR
LENSAR sg&a expenses from 2019 to 2024. Sg&a expenses can be defined as the sum of all selling, general and administrative expenses.
| LENSAR Annual SG&A Expenses (Millions of US $) |
|
|---|---|
| 2024 | $26 |
| 2023 | $26 |
| 2022 | $27 |
| 2021 | $24 |
| 2020 | $24 |
| 2019 | $17 |
| 2018 | $16 |
| LENSAR Quarterly SG&A Expenses (Millions of US $) |
|
|---|---|
| 2024-12-31 | $7 |
| 2024-09-30 | $6 |
| 2024-06-30 | $7 |
| 2024-03-31 | $7 |
| 2023-12-31 | $6 |
| 2023-09-30 | $5 |
| 2023-06-30 | $8 |
| 2023-03-31 | $7 |
| 2022-12-31 | $7 |
| 2022-09-30 | $6 |
| 2022-06-30 | $8 |
| 2022-03-31 | $6 |
| 2021-12-31 | $6 |
| 2021-09-30 | $7 |
| 2021-06-30 | $6 |
| 2021-03-31 | $6 |
| 2020-12-31 | $9 |
| 2020-09-30 | $6 |
| 2020-06-30 | $4 |
| 2020-03-31 | $5 |
| 2019-12-31 | |
| 2019-09-30 | $4 |
| 2018-12-31 | |
| Sector | Industry | Market Cap | Revenue |
|---|---|---|---|
| Medical | MED INSTRUMENTS | $0.165B | $0.053B |
| LENSAR Inc. is a commercial-stage medical device company. It focuses on designing, developing and marketing an advanced femtosecond laser system for the treatment of cataracts and the management of pre-existing or surgically induced corneal astigmatism. LENSAR Inc. is based in Orlando, Florida. | |||